INTRODUCTION: Erlotinib and Gefitinib (EGFRi) are small molecules specifically inhibiting epidermal growth factor receptor (EGFR). We present here data of an exploratory study evaluating EGFRi monotherapy in patients with recurrent or progressive malignant glioma. PATIENTS: 21 patients with recurrent or progressive malignant glioma were included in this study. EGFRi treatment was started at a median of 1.8 years (range 0.54 to 10.95) after initial surgery. 20/21 patients had undergone radiotherapy and all patients had received at least one (range 1 to 5, median 2) line of systemic antineoplastic therapy. Patients received 100 or 150 mg Erlotinib or 250 mg Gefitinib orally per day. RESULTS: Median age at primary diagnosis was 47.9 years (range 31.9 to 76 years). 18 patients received a total of 92.8 months (median 3.03) of Erlotinib treatment and 3 patients received a total of 16.1 months (median 6.06) of Gefitinib treatment. The best responses were partial remission in one patient receiving Erlotinib and in two patients receiving Gefitinib, respectively. Median time to progression was 3.05 months. Six months after start of EGFRi treatment, 4/21 (19%) patients were progression-free and 6/21(29%) patients were alive. Expression of EGFRwt, EGFRvIII, PTEN, phospho-Akt or EGFRvIII/PTEN co-expression in tumor cells did not significantly associate with time to progression or survival time. In one patient EGFRi administration had to be discontinued due to toxicity (grade 3 rash). CONCLUSION: EGFRi monotherapy is associated with therapeutic efficacy in only a small fraction of patients with malignant gliomas. Biomarkers reliably predicting tumor response to EGFRi need to be identified.
INTRODUCTION:Erlotinib and Gefitinib (EGFRi) are small molecules specifically inhibiting epidermal growth factor receptor (EGFR). We present here data of an exploratory study evaluating EGFRi monotherapy in patients with recurrent or progressive malignant glioma. PATIENTS: 21 patients with recurrent or progressive malignant glioma were included in this study. EGFRi treatment was started at a median of 1.8 years (range 0.54 to 10.95) after initial surgery. 20/21 patients had undergone radiotherapy and all patients had received at least one (range 1 to 5, median 2) line of systemic antineoplastic therapy. Patients received 100 or 150 mg Erlotinib or 250 mg Gefitinib orally per day. RESULTS: Median age at primary diagnosis was 47.9 years (range 31.9 to 76 years). 18 patients received a total of 92.8 months (median 3.03) of Erlotinib treatment and 3 patients received a total of 16.1 months (median 6.06) of Gefitinib treatment. The best responses were partial remission in one patient receiving Erlotinib and in two patients receiving Gefitinib, respectively. Median time to progression was 3.05 months. Six months after start of EGFRi treatment, 4/21 (19%) patients were progression-free and 6/21(29%) patients were alive. Expression of EGFRwt, EGFRvIII, PTEN, phospho-Akt or EGFRvIII/PTEN co-expression in tumor cells did not significantly associate with time to progression or survival time. In one patient EGFRi administration had to be discontinued due to toxicity (grade 3 rash). CONCLUSION: EGFRi monotherapy is associated with therapeutic efficacy in only a small fraction of patients with malignant gliomas. Biomarkers reliably predicting tumor response to EGFRi need to be identified.
Authors: Sunil Krishnan; Paul D Brown; Karla V Ballman; John B Fiveash; Joon H Uhm; Caterina Giannini; Kurt A Jaeckle; Francois J Geoffroy; L Burt Nabors; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2006-04-19 Impact factor: 7.038
Authors: Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern Journal: J Am Acad Dermatol Date: 2006-10 Impact factor: 11.527
Authors: Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel Journal: N Engl J Med Date: 2005-11-10 Impact factor: 91.245
Authors: Y Marie; A F Carpentier; A M P Omuro; M Sanson; J Thillet; K Hoang-Xuan; J-Y Delattre Journal: Neurology Date: 2005-04-26 Impact factor: 9.910
Authors: A Perren; L P Weng; A H Boag; U Ziebold; K Thakore; P L Dahia; P Komminoth; J A Lees; L M Mulligan; G L Mutter; C Eng Journal: Am J Pathol Date: 1999-10 Impact factor: 4.307
Authors: Martin J van den Bent; Alba A Brandes; Roy Rampling; Mathilde C M Kouwenhoven; Johan M Kros; Antoine F Carpentier; Paul M Clement; Marc Frenay; Mario Campone; Jean-Francois Baurain; Jean-Paul Armand; Martin J B Taphoorn; Alicia Tosoni; Heidemarie Kletzl; Barbara Klughammer; Denis Lacombe; Thierry Gorlia Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Y Waerzeggers; P Monfared; T Viel; A Faust; K Kopka; M Schäfers; B Tavitian; A Winkeler; A Jacobs Journal: Br J Radiol Date: 2011-12 Impact factor: 3.039
Authors: Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist Journal: Expert Rev Mol Med Date: 2011-05-13 Impact factor: 5.600
Authors: Jeffrey J Raizer; Lauren E Abrey; Andrew B Lassman; Susan M Chang; Kathleen R Lamborn; John G Kuhn; W K Alfred Yung; Mark R Gilbert; Kenneth A Aldape; Patrick Y Wen; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Frank Lieberman; Timothy F Cloughesy; H Ian Robins; Janet Dancey; Michael D Prados Journal: Neuro Oncol Date: 2009-12-14 Impact factor: 12.300
Authors: Jeffrey J Olson; Lakshmi Nayak; D Ryan Ormond; Patrick Y Wen; Steven N Kalkanis; Timothy Charles Ryken Journal: J Neurooncol Date: 2014-04-17 Impact factor: 4.130